Aegea Biotechnologies, Inc. Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition
Aegea Biotechnologies has been selected as a semi-finalist in the $5 million XPRIZE Rapid COVID Testing competition. This initiative aims to enhance COVID-19 testing capabilities significantly. Aegea's innovative PCR-based assay utilizes proprietary Switch-Blocker technology, allowing for high sensitivity in detecting SARS-CoV-2. Collaborating with Biocept, Aegea aims to commercialize this test swiftly, which stands to offer affordable, fast, and detailed strain-specific results, potentially aiding in managing the pandemic effectively.
- Selected as a semi-finalist in the $5 million XPRIZE Rapid COVID Testing competition.
- Developing a highly sensitive PCR-based assay in partnership with Biocept.
- The assay can detect low viral RNA levels, potentially identifying asymptomatic infections.
- Designed to distinguish high-risk and low-risk strains of SARS-CoV-2, aiding medical decision-making.
- None.
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Aegea Biotechnologies, Inc. (www.aegeabiotech.com, "Aegea"), a biotechnology company focusing on the development and commercialization of next generation nucleic acid and clinical diagnostic technologies, announces that it has been selected as a semi-finalist in the prestigious XPRIZE competition for rapid COVID testing.
XPRIZE is renowned for its worldwide competitions to solve humanity's most important challenges. The
Aegea advanced to the XPRIZE Rapid COVID Testing Semi-Finals after sharing results of a new, highly sensitive, quantitative PCR-based assay for detecting SARS-CoV-2 (COVID-19 virus) that Aegea designed and is developing and validating clinically in collaboration with Biocept, Inc. (NASDAQ:BIOC). The COVID-19 PCR assay utilizes Switch-Blocker technology, which is patent protected in the United States and in 10 major international territories and is jointly owned by Aegea and Biocept. Under an associated cross-license agreement, Aegea has exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology, where Biocept has used the technology to identify and report rare cancer associated mutations in more than 20,000 cancer patients to aid medical treatment decisions.
In addition to high sensitivity and specificity, affordability and fast turnaround time, Aegea's test is designed to provide additional information on specific strain types of SARS-CoV-2.
"We are pleased to compete for the XPRIZE and to put our inventions and ideas towards solving an urgent global health need. Aegea's new COVID-19 test utilizes the single nucleotide discrimination capacities of the patented Switch-Blocker technology to differentiate itself from other COVID-19 PCR assays," said Lyle J. Arnold, Ph.D., Founder & CEO of Aegea. "Our assay is designed to detect low copy numbers of viral RNA, therefore it could potentially detect the viral load at lower levels than other PCR-based assays. This could be enormously helpful in reducing the infection rate, because it has been reported that asymptomatic patients are able to infect others. At the same time, due to its high sensitivity, our assay should allow multiple patient samples to be pooled into a single assay, to greatly speed up the number of patients tested. Additionally, our COVID-19 PCR assay is designed with the ability to identify high-risk and low-risk strains of SARS-CoV-2, which could significantly aid medical decision-making, for identifying patients most in need of hospitalization. It also distinguishes SARS-CoV-2, which is associated with COVID-19, from other common forms of the SARS virus."
Aegea's Chief Business Officer, Stella M. Sung, Ph.D., adds, "In addition to applying proprietary science, Aegea has established strategic collaborations that will enable us to quickly scale and commercialize our COVID-19 PCR test. Biocept, has a CLIA-certified, CAP-accredited high-complexity molecular lab, and has the ability to run our high throughput, multiplexed assays. Biocept also has a right of first negotiation for use of the assay in its clinical laboratory. Separately, Tauriga Sciences (OTC/QB: TAUG) has extensive relationships with manufacturers and distributors to help with supply chain issues and commercial opportunities. Being a semi-finalist for the XPRIZE will further accelerate Aegea's development and commercialization timelines. Our immediate goal is to get a fast, accurate, affordable, accessible, information-rich test to the market. Our long-term purpose is to equip our global community with a powerful tool for managing pandemics and for saving lives."
About Aegea Biotechnologies
Aegea Biotechnologies, Inc. located in San Diego, California, is a biotechnology company focusing on the development and commercialization of next generation nucleic acid technologies. A primary focus for the company is nucleic acid technology innovations that embrace molecular diagnostic assays, qPCR technologies, sequencing methods including both Sanger and NGS, and rapid point-of-care COVID-19 testing. Aegea has been granted 11 US patents, and 34 foreign equivalents world-wide. Aegea has complementary collaborations with Biocept (Nasdaq: BIOC) and Tauriga Sciences (OTC/QB: TAUG) for developing and commercializing its COVID-19 tests. www.aegeabiotech.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aegea-biotechnologies-inc-advances-to-semi-finals-of-the-5m-xprize-rapid-covid-testing-competition-301129912.html
SOURCE Aegea Biotechnologies, Inc.
FAQ
What is Aegea Biotechnologies' recent achievement regarding COVID-19 testing?
What technology does Aegea use for its COVID-19 test?
Who is Aegea partnering with for COVID-19 test development?
What are the benefits of Aegea's COVID-19 assay?
What is the goal of the XPRIZE Rapid COVID Testing competition?
